Guggenheim Reiterates “Neutral” Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “neutral” rating reiterated by analysts at Guggenheim in a report issued on Friday,Benzinga reports.

KROS has been the subject of a number of other research reports. Oppenheimer lowered their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Wedbush reiterated an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $70.22.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $11.51 on Friday. The company has a market capitalization of $466.43 million, a P/E ratio of -2.20 and a beta of 1.43. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00. The company’s fifty day moving average is $38.65 and its two-hundred day moving average is $47.61.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period last year, the firm posted ($1.33) EPS. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. As a group, equities analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KROS. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new position in shares of Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics in the 3rd quarter valued at $213,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.